Skip to main content

Advertisement

Table 3 FRAX597 combined with gemcitabine increases survival in a mouse orthotopic pancreatic cancer model

From: FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine

Treatment Rates ratio 95 % CI P value
Control 7.0 1.8 ± 27.0 0.005
Gemcitabine 2.7 1.0 ± 8.7 0.09
Gemcitabine + FRAX 1.0 (ref)   
  1. The overall statistics for the stratified Cox regression analysis were: χ 2 (2) = 9.9, p = 0.007